BlackRock Capital Allocation Term Trust (BCAT) Stock Price & Analysis
BlackRock Capital Allocation Term Trust (BCAT) is trading at USD 13.22, up 0.15% today, as of October 23, 2026 at 16:31 UTC (US market open; quotes may be delayed), according to Nexqual market data.
BCAT last closed at USD 13.2; today's session has ranged USD 13.02–13.25 on volume of 237,301 shares. Market capitalization is $1.40B, with a 52-week range of USD 12.92–16.2 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 16:38 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BCAT.md
Key facts (BCAT)
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $570K; 1 not under a Rule 10b5-1 plan ($570K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: None.
- Total return with dividends: 1Y +12.7% vs S&P 500 +14.6%; 5Y +39.2% vs S&P 500 +77.3%.
Insider sales (SEC Form 4, open-market, last ~7 months) (BCAT)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-07-13 | Rieder Richard M | 35,734 | $570K | 11.6% | No | Too little history (no open-market trades in 2024 or 2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BCAT)
Consensus None.
Total return (dividends reinvested) (BCAT)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +12.7% | +39.2% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | +12.8% | +6.8% |
| Volatility (annualized) | 14.7% | 15.0% |
| Max drawdown | -16.1% (Sep 2026→Oct 2026) | -28.1% (Nov 2021→Oct 2022) |
BCAT analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 23, 2026 at 16:38 UTC)
| Price | USD 13.22 |
|---|---|
| Change | ▲ 0.15% (up) |
| Previous Close | USD 13.2 |
| Open | USD 13.11 |
| Day Range | USD 13.02 – 13.25 |
| 52-Week Range | USD 12.92 – 16.2 |
| Volume | 237,301 shares |
| Market Cap | $1.40B |
| Exchange | NYQ |
Technical Analysis (BCAT)
Nexqual's technical model rates BCAT "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of October 23, 2026 at 16:38 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 27.58 (oversold) |
| vs SMA50 | Below (USD 14.57) |
| MACD | -0.36 (negative) |
Analyst Ratings (BCAT)
Wall Street analysts rate BCAT "None", per Nexqual as of October 23, 2026 at 16:38 UTC.
| Consensus Rating | None |
|---|
Earnings (BCAT)
Source: Nexqual, October 23, 2026 at 16:38 UTC.
Financials & Fundamentals (BCAT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
Source: Nexqual, October 23, 2026 at 16:38 UTC.
Financial Health Score (BCAT)
Nexqual rates BlackRock Capital Allocation Term Trust's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 16:38 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% (last 12 months) |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Ownership (BCAT)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +18.40% |
| Shares Outstanding | 106.28M |
Source: Nexqual, October 23, 2026 at 16:38 UTC.
Major Backers & Investors (BCAT)
Notable institutional backers of BlackRock Capital Allocation Term Trust include Morgan Stanley, Wells Fargo & Company, Penserra Capital Management LLC, according to Nexqual as of October 23, 2026 at 16:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 3.42% |
| Wells Fargo & Company | 2.31% |
| Penserra Capital Management LLC | 1.53% |
| Amplify ETF Trust-Amplify CEF High Income ETF | 1.52% |
| Cohen & Steers Inc. | 1.49% |
| Bank of America Corporation | 1.47% |
| UBS Group AG | 1% |
| Invesco | 0.66% |
Source: Nexqual, October 23, 2026 at 16:38 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BXSL | Blackstone Secured Lending Fund | USD 23.54 | ▼ 1.57% |
| VCTR | Victory Capital Holdings, Inc. | USD 107.23 | ▼ 0.15% |
| PDI | PIMCO Dynamic Income Fund | USD 14.33 | ▲ 0.21% |
| AMG | Affiliated Managers Group, Inc. | USD 389.47 | ▼ 1.53% |
| SEIC | SEI Investments Company | USD 103.25 | ▼ 1.2% |
| IVZ | Invesco Ltd | USD 28.5 | ▼ 1.01% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:38 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt